rs1060500676
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP3_ModeratePP5
The NM_005188.4(CBL):āc.1165A>Gā(p.Lys389Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_005188.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CBL | NM_005188.4 | c.1165A>G | p.Lys389Glu | missense_variant | Exon 8 of 16 | ENST00000264033.6 | NP_005179.2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1460302Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 726616
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
CBL-related disorder Pathogenic:2
The CBL c.1165A>G (p.Lys389Glu) missense change replaces lysine with glutamic acid at codon 389 of the CBL gene and is absent in population databases including gnomAD v2.1.1 (PM2_supporting; https://gnomad.broadinstitute.org/). The lysine residue is located in the RING finger domain which is a known mutational hotspot in myeloid malignancies and the location of germline pathogenic variants causing Noonan syndrome-like disorder (PM1; PMID: 20619386). This variant has been identified in an individual with juvenile myelomonocytic leukemia (JMML) in which the tumor exhibited a second pathogenic variant in the CBL gene (PS4_supporting, PP4; internal data). This is consistent with the mechanism of leukemogenesis in individuals with JMML and pathogenic germline variants in CBL (PMID: 20694012, 33375775). Seven of seven in silico tools predict a deleterious effect of this variant on protein function (PP3). There is a different pathogenic variant (p.Lys389Thr) previously reported at this codon (ClinVar Accession: SCV001826631.1, SCV001445234.1). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied: PS4_supporting, PM1, PM2_supporting, PP3, PP4. -
- -
not provided Pathogenic:1
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 20619386, 22315494) -
RASopathy Uncertain:1
This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 389 of the CBL protein (p.Lys389Glu). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CBL-related conditions. ClinVar contains an entry for this variant (Variation ID: 405365). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CBL protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at